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Window” of Platelet Reactivity to
Adenosine Diphosphate*
Udaya S. Tantry, PHD, Paul A. Gurbel, MDA decade ago, small observational studiesusing light transmittance aggregometry sug-gested that post-stenting ischemic event
occurrences were not linearly related to on-
treatment platelet reactivity (OPR) levels but instead
largely occurred above a moderate threshold level
(1,2). For example, in the CREST (Carotid Revascular-
ization Endarterectomy Versus Stenting Trial) study
of 20 patients with previous stent thrombosis (ST)
and 100 age-matched patients without ST, >40%
maximal platelet aggregation in response 20 mM
adenosine diphosphate (ADP) was associated with
ST (3). Subsequently, a number of studies using
various platelet function assays including the most
widely used VerifyNow P2Y12 assay demonstrated
similar OPR cutoff values associated post-stenting
ischemic event occurrences and termed an upper cut-
off value as high OPR (HPR) (4). It was hypothesized
that adequate protection against ischemic events
with antiplatelet therapy is achieved by low to mod-
erate levels of OPR in the majority of patients,
whereas markedly low levels of OPR are associated
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ing dual antiplatelet therapy with a P2Y12 receptor in-
hibitor and aspirin, similar to the international
normalized ratio for warfarin therapy (5,6).
How far has this translational research ﬁeld ad-
vanced since then? Recent prospective, randomized
trials of personalized antiplatelet therapy have failed
to demonstrate the beneﬁt of platelet function testing
in improving outcomes in patients with HPR (7,8). It
should be acknowledged that these trials are associ-
ated with major limitations, such as the enrollment of
low-risk patients, which resulted in low event rates
and lack of power and the use of high-dose clopi-
dogrel, which is not an optimal strategy to overcome
HPR and to improve clinical outcomes. In the ADAPT-
DES (Assessment of Dual Antiplatelet Therapy With
Drug-Eluting Stents) study, a multinational prospec-
tive registry of 8,582 patients (w50% of patients with
acute coronary syndrome), HPR deﬁned as>208 P2Y12
reaction units (PRUs) was independently associated
with an w2-fold increased risk of 2-year deﬁnite/
probable ST (hazard ratio [HR]: 1.84, p ¼ 0.009) and
inversely correlated with major bleeding (HR: 0.82,
p ¼ 0.02), with a trend toward all-cause deathSEE PAGE 1978(HR: 1.27, p ¼ 0.06) (9). In this issue of JACC: Cardio-
vascular Interventions, Kirtane et al. (10) further
analyzed ADAPT-DES platelet reactivity data catego-
rized in quintiles (a continuous variable rather than
dichotomous variable that was done with HPR) in
relation to clinical outcomes. They found that PRUs
were associated in a monotonic fashion with ST and
that ST was independently associated with the highest
PRU quintile. The clinically relevant bleeding was
independently associated with lowest PRU quintile,
and bleeding events were equally distributed among
other quintiles. Finally, all-cause mortality was only
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1989associated with a higher PRU quintile in an unad-
justed analysis.
The observations of Kirtane et al. in the largest
dataset of platelet reactivity thus far reinforce what
was observed in smaller studies a decade ago. It was
demonstrated that the HPR cutoff values have high
negative predictive value for thrombotic event
occurrence, but the positive predictive value is low
(4). The latter is due to very low thrombotic event
rate and although HPR is a major determinant of the
thrombotic event occurrences, clinical events are
dependent on multiple factors in addition to HPR.
Therefore, HPR may not be a standalone risk factor,
but should be part of risk algorithm along with
makers akin to CRUSADE (Can Rapid risk stratiﬁca-
tion of Unstable angina patients Suppress ADverse
outcomes with Early implementation of the ACC/AHA
guidelines) bleeding score or GRACE (Global Registry
of Acute Coronary Events) risk score to improve
risk prediction and facilitate personalization of anti-
platelet therapy.
Unlike a strong and “monotonically increasing”
relationship between platelet reactivity and stent
thrombosis, clinically relevant bleeding was inde-
pendently associated with the lowest quintile of PRU
only. The latter is not surprising. The underlying
mechanisms of bleeding are more complex and het-
erogeneous in origin, unlike coronary thrombotic
events. Second, it is likely that only a very high level
of platelet inhibition appears to reliably inﬂuence
primary hemostasis. Earlier studies with glycoprotein
IIb/IIIa antagonist (abciximab) demonstrated that
bleeding time was affected only with 90% receptorblockade. Even with w80% receptor blockade, a de-
gree associated with signiﬁcant inhibition of platelet
aggregation, the bleeding time was only mildly
affected (11). The results of the current analysis of
ADAPT-DES are in line with the latter study and early
results of other smaller studies (12).
Finally, the absence of an independent relation-
ship between higher PRU and mortality is not sur-
prising. The latter observation is similar to the ﬁnding
of TRILOGY ACS (A Comparison of Prasugrel and
Clopidogrel in Acute Coronary Syndrome Subjects)
platelet function substudy (13). Multiple risk fac-
tors and covariates such as diabetes, old age, prev-
ious myocardial infarction, renal insufﬁciency, and
smoking status may inﬂuence mortality by their
effect on platelet physiology and thereby could have
masked the independent association. In fact, uni-
variate associations may be more important for the
treating physician who is unable to adjust test results
for multiple variables at the bedside (13).
Kirtane et al. (10) provide much more robust evi-
dence of the “therapeutic widow” concept of platelet
reactivity. However, only a large prospective person-
alized therapy trial that demonstrates improved out-
comes when patients are within the window will
advance this interesting ﬁeld and silence the queries
about whether HPR is a modiﬁable risk factor.
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